Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company that focuses on pioneering novel cancer therapies. The company is engaged in the discovery, development, and investigation of cancer treatments, particularly those addressing high unmet medical needs.

COM:KARYOPHARM

Karyopharm Therapeutics Inc.

Last Close

0.78

22/11 15:27

Market Cap

97.44M

Beta: -

Volume Today

59.22K

Avg: -

Financials Not Available